4.7 Review

Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis

Journal

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 7, Issue 12, Pages 1279-1286

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2009.06.031

Keywords

-

Funding

  1. Procter and Gamble
  2. Lexicon Genetics, Inc
  3. Astellas Pharma US, Inc
  4. Pharma Frontiers, Ltd
  5. Callisto Pharmaceuticals
  6. AstraZeneca
  7. Addex Pharma
  8. Ferring Pharma
  9. Salix
  10. MGI Pharma
  11. McNeil Consumer
  12. Microbia
  13. Dynogen
  14. Conexus
  15. Novartis
  16. Metabolic Pharmaceuticals
  17. Takeda
  18. GlaxoSmithkline
  19. Toga
  20. AxCan Pharma
  21. Nycomed
  22. Johnson and Johnson
  23. American College of Gastroenterology

Ask authors/readers for more resources

BACKGROUND & AIMS: Small intestinal bacterial over-growth (SIBO) has been proposed as an etiologic factor in irritable bowel syndrome (IBS), but evidence is conflicting. We conducted a systematic review and meta-analysis of the prevalence of SIBO in IBS. METHODS: MEDLINE and EMBASE were searched up to November 2008. Case series and case-control studies applying diagnostic tests for SIBO in unselected adults meeting diagnostic criteria for IBS were eligible. Prevalence of a positive test for SIBO was extracted and pooled for all studies, and compared between cases and controls using an odds ratio and 95% confidence interval (CI). RESULTS: Twelve studies were identified containing 1921 subjects meeting criteria for IBS. Pooled prevalence of a positive lactulose or glucose hydrogen breath test was 54% (95% CI, 32%-76%) and 31% (95% CI, 14%-50%), respectively, with statistically significant heterogeneity between study results. Prevalence of a positive jejunal aspirate and culture was 4% (95% CI, 2%-9%). The pooled odds ratio for any positive test for SIBO in cases compared with healthy asymptomatic controls was 3.45 (95% CI, 0.9-12.7) or 4.7 (95% CI, 1.7-12.95), depending on the criteria used to define a positive test, with statistically significant heterogeneity for both. CONCLUSIONS: Prevalence of SIBO in individuals meeting diagnostic criteria for IBS was highest with breath testing. The prevalence in cases with IBS compared with controls varied according to criteria used to define a positive test. The role of testing for SIBO in individuals with suspected IBS remains unclear.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available